Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer

A technology for metabolizing small molecules and early diagnosis, applied in material separation, analysis materials, instruments, etc., can solve the problems of high missed or misdiagnosed rate, low detection rate of markers, limited clinical application, etc. Improve sensitivity and specificity, and achieve the effect of accurate judgment

Active Publication Date: 2020-03-20
CHINA PHARM UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, imaging and sputum exfoliation cytology are still the main means of screening for early lung cancer, especially the pathological types of lung cancer are diverse, and clinical diagnosis mainly relies on imaging examinations: chest X-ray, CT (computed tomography, computerized tomography) ), PET-CT (Positron EmissionTomography / Computer Tomography, Positron Emission Tomography, Positron Emission Computed Tomography), but these examinations have certain radiation risks, high cost defects, and relatively high rates of missed or misdiagnosed
Other pathological examinations, such as bronchoscopic lung biopsy and CT-guided percutaneous lung biopsy, can diagnose lung cancer, but they will cause great trauma to the human body
In addition, the existing tumor markers are mainly gene expression products and proteins, and the detection rate of these markers is low, which limits the clinical application to a certain extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer
  • Application of a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer
  • Application of a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0043] one. Objectives and methods

[0044] 1. Specimen collection and processing

[0045] Whole blood samples from 43 healthy volunteers and 43 patients with preoperative lung cancer were collected and placed in the 2In EDTA blood collection tubes, centrifuge at 4°C, 8000rpm for 10min, take the upper layer of plasma and EP tubes, and quickly put them in -80°C and refrigerate for testing. Take 20 µL each from the plasma samples of healthy volunteers, mix well to prepare QC samples, and store them in the same way.

[0046] 2. Main reagents

[0047] Heptadecanoic acid (content>99.9%), methoxyamine hydrochloride (MOX, content>99.9%), N-methyltrimethylsilyltrifluoroacetamide (MSTFA, content>99.9%) and pyridine were purchased from Sigma-Aldrich (St.Louis, MO, USA); formic acid, methanol, and acetonitrile (HPLC reagents, Merck, Germany); ultrapure water (MILIQ ultrapure water device from Milipore, USA).

[0048] 3. Detection and identification of differential metabolites in pla...

Embodiment 2

[0088] Embodiment 2: the preparation of detection kit:

[0089] Based on the small molecule markers of plasma metabolism provided by the present invention, a detection kit is prepared, which contains the following components:

[0090] Standards for small molecule markers of plasma metabolism: containing propionic acid, aspartic acid, glucofuranoside, citric acid, allose, talose, galactopyranose, pyruvate, tryptophan, leucylproline Amino acid, glycerophosphatidylcholine, oleoylcarnitine, lysophosphatidylcholine (18:3), lysophosphatidylcholine (18:2), lysophosphatidylcholine (18:1), lysophosphatidylcholine Choline (22:6), Lysophosphatidylethanolamine (20:0), Lysophosphatidylethanolamine (18:2), Tyrosylvaline;

[0091] Plasma metabolite extraction solvent: a mixed solution of methanol and acetonitrile at a ratio of 1:1, 80% aqueous methanol solution (for UPLC-IT-TOF / MS sample preparation); methanol, methoxyamine hydrochloride and N-methyl trimethyl Silicon-based trifluoroacetam...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a group of plasma metabolism micromolecular markers related to lung cancer early diagnosis and an application thereof. The plasma metabolism micromolecular markers comprise oneor more of the following markers: propionic acid, aspartic acid, furan glucoside, citric acid, allose, talose, galactopyranose, pyruvic acid, tryptophan, leucyl proline, glyceryl phosphoryl choline,oleoyl carnitine, lysophosphatidyl choline (18:3), lysophosphatidyl choline (18:2), lysophosphatidyl choline (18:1), lysophosphatidyl choline (22:6), lysophosphatidyl ethanolamine (20:0), lysophosphatidyl ethanolamine (18:2), and complex aminoacyl valine. Compared with the traditional protein biomarkers, the group of the provided markers has the stronger outcome relevance with diseases, and is stable, minimally invasive, and easy to detect, capable of greatly improving the sensitivity and the specificity of the related disease diagnosis, and suitable for the early clinical diagnosis and monitoring of lung cancer.

Description

technical field [0001] The invention belongs to the technical field of biochemistry, and in particular relates to a group of plasma metabolic small molecule markers related to early diagnosis of lung cancer and applications thereof. Background technique [0002] Lung cancer is one of the tumors with increasing morbidity and mortality in the past half century, and it is the most harmful malignant tumor to human health and life. The 5-year survival rate of lung cancer has not improved significantly in the past 20 years, about 14%. Because most lung cancer patients are found at advanced stage, only palliative treatment can be performed, resulting in short survival time. Therefore, early diagnosis and early treatment will significantly improve the survival period of patients and increase the survival rate of lung cancer patients. At present, imaging and sputum exfoliation cytology are still the main means of screening for early lung cancer, especially the pathological types of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/88
CPCG01N30/88G01N2030/8822
Inventor 黄寅张尊建许风国惠慧华云飞杨旭萍李琳睿
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com